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Abstract
Background: Exposure of chondroitin sulfate A (CS-A) on the surface of activated platelets is well established. The aim of the
present study was to investigate to what extent CS-A contributes to the binding of the complement recognition molecule
C1q and the complement regulators C1 inhibitor (C1INH), C4b-binding protein (C4BP), and factor H to platelets.
Principal Findings: Human blood serum was passed over Sepharose conjugated with CS-A, and CS-A-specific binding
proteins were identified by Western blotting and mass spectrometric analysis. C1q was shown to be the main protein that
specifically bound to CS-A, but C4BP and factor H were also shown to interact. Binding of C1INH was dependent of the
presence of C1q and then not bound to CS-A from C1q-depleted serum. The specific interactions observed of these proteins
with CS-A were subsequently confirmed by surface plasmon resonance analysis using purified proteins. Importantly, C1q,
C4BP, and factor H were also shown to bind to activated platelets and this interaction was inhibited by a CS-A-specific
monoclonal antibody, thereby linking the binding of C1q, C4BP, and factor H to exposure of CS-A on activated platelets. CS-
A-bound C1q was also shown to amplify the binding of model immune complexes to both microtiter plate-bound CS-A and
to activated platelets.
Conclusions: This study supports the concept that CS-A contributes to the binding of C1q, C4BP, and factor H to platelets,
thereby adding CS-A to the previously reported binding sites for these proteins on the platelet surface. CS-A-bound C1q
also seems to amplify the binding of immune complexes to activated platelets, suggesting a role for this molecule in
immune complex diseases.
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Introduction
Glycosaminoglycans (GAG) are important structures in the
extracellular matrix (ECM). Many GAGs are attached directly to
cell membrane proteins and facilitate the binding of soluble
proteins to the surface. Well-known GAGs include heparin,
heparan sulfate, dermatan sulfate, and chondroitin sulfate [1].
Chondroitin sulfate (CS) is a GAG that consists of an anionic
linear, unbranched polysaccharide of alternating disaccharide
units of glucuronic acid and N-acetylgalactosamine, connected to
a protein core via a tetrasaccharide linker [2]. Although
conventionally viewed as important because of its structural role
in the extracellular matrix, CS has recently received growing
attention because of its other cellular functions, such as in cell
communication [3,4]. The sulfation pattern, deacetylation, and
epimerization of the structure create diversity among the CS
family and are critical for the specific activity of its individual
members [4]. In mammals, the galactosamine unit is most often
monosulfated at position C-4 (as in the case of CS-A) or C-6 (as in
CS-C) [5]. In addition to monosulfated CS-A and CS-C, other
forms of CS have been described, such as CS-D and CS-E, which
both are disulfated [5]. Dermatan sulfate, formerly known as CS-
B, is often described together with CS but differs more radically
from the other forms of CS, mainly because of its frequent
epimerization of the glucoronic acid to iduronic acid [6]. CS is the
most abundant GAG in human plasma (70–80% of all GAGs),
with CS-A representing half of this fraction and the remainder
being non-sulfated [5].
A number of cell types express CS on their surfaces, including
neurons, glial cells and platelets [7]. The fact that CS-A represents
the main GAG in platelets has been well established by both
biochemical and histologic techniques [8,9]. Rapid release of CS-
A from platelets has been shown to occur in response to a variety
of agonists, including ADP, collagen, adrenalin, and thrombin,
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12889resulting in a rise in plasma CS-A by up to 2 mg/mL within 3 min
after activation [10]. CS-A has been implicated to be localized in
the platelet a-granules [10,11,12], and has been shown to be
exposed on the surface of platelets after activation [9]. The CS-A
present in platelets, unlike that in blood plasma, is fully sulfated,
and its average molecular mass has been estimated to be
approximately 28 kDa [8]. An over-sulfated form of CS was
recently described to be contaminating commercial heparin
preparations. These heparin preparations caused fatal anaphyla-
toxic reactions after injection/infusion due to the over-sulfated CS
which activated both the complement and the contact systems
[13].
We have previously shown that CS-A released from activated
platelets activates the complement system in the fluid phase [14].
C1q was identified as the recognition molecule, since it bound to
CS-A in high amounts. Complement activation was abolished
when C1q-depleted serum was used. We have also shown that
platelets activated with the thrombin receptor activating peptide
(TRAP) expose CS-A and bind complement components C1q, C4,
C3, and C9 [15]. TRAP acts as a tethered ligand for the thrombin
receptor PAR-1 and is able to cause full receptor activation in the
absence of thrombin [16,17]. However, the binding of comple-
ment proteins is independent of complement activation, and
inhibition of complement at the stage of C1q or C3 does not affect
the binding of the complement components. This suggests that the
complement system is stringently regulated on the platelet surface,
both regarding initiation and amplification.
In previous studies, we have found a very high avidity of C1q
for CS-A, which is reflected in the relative inability of soluble CS-
A to compete with the binding of C1q to surface-conjugated CS-A.
We also observed that high amounts of C3 bound in a non-
activated from, as C3(H2O) which initiated speculations regarding
the impact of soluble complement inhibitors at the platelet surface.
In the present study, we have investigated the binding to both
immobilized and platelet-exposed CS-A of C1q and of comple-
ment-regulating proteins known to interact with GAGs. We also
investigated the functional capacity of CS-A-bound C1q with
regard to the binding of model immune complexes to the platelet
surface.
Results
Binding of serum proteins to Sepharose-bound CS-A
Serum or C1q-depleted serum was passed over Sepharose
conjugated with CS-A or over a control Sepharose column
without CS-A. After washing, the bound serum proteins were
eluted with increasing salt concentrations. The eluted proteins
were concentrated and then run on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions, and the polypeptide bands were identified by mass
spectrometric analysis and Western blotting (Fig. 1). Immuno-
globulin-derived chains (m, a, c, and k) from serum sufficient and
depleted of C1q were shown to bind to both the control and CS-A
conjugated columns (Fig. 1 A). The polypeptide bands with the
strongest intensity that were specific for the CS-A conjugated
Sepharose were associated with C1q. In control experiments it was
demonstrated that the C1q binding was not dependent on bound
IgG since equivalent binding of C1q occurred from IgG depleted
serum as compared to intact serum (data not shown). Additional
bands specifically binding to CS-A and visualized on the gels were
identified as fibronectin, thrombospondin, plasminogen, throm-
bin-antithrombin complex and human serum albumin. When we
characterized the binding of the complement regulators C1INH,
C4BP, and factor H by Western blotting (Fig. 1B), we found that
in the presence of C1q, C1INH, factor H and C4BP bound to the
column, but after C1q depletion, binding of C1INH was no longer
seen, suggesting that the protein bound to CS-A in association
with C1q. Factor H and C4BP bound with higher intensity in the
absence of C1q. Identified proteins are listed in Table 1.
Evaluation of the binding of complement proteins to
immobilized CS-A by surface plasmon resonance
The interaction profiles of C1q, C1INH, C4BP and factor H
were further studied by surface plasmon resonance analysis (Fig. 2).
CS-A was immobilized to a high density on a carboxylated HC500
sensor chip, and purified proteins and monoclonal antibodies
Figure 1. Binding of proteins to CS-A-Sepharose and control
Sepharose. Proteins from serum and C1q-depleted serum that bound
to the CS-A affinity (CS-A) and control (Sepharose) columns were eluted
with increasing salt concentrations; the eluted proteins were concen-
trated, subjected to SDS-PAGE, and visualized on a gel (A) using
Coomassie staining or by reaction with specific antibodies in Western
blotting (B). The numbered bands in A were cut out and identified by
mass spectrometry; the identification was further verified by Western
blot analysis.
doi:10.1371/journal.pone.0012889.g001
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antibodies, only CS-56 but not 2H6 showed specificity against
immobilized CS-A. Whereas C1INH showed no significant
binding even at the highest concentration (data not shown),
specific protein interactions with CS-A were found for C1q, C4BP
and factor H, thereby confirming the affinity chromatography
results. Normalization of the binding responses by molecular
weight revealed C1q as the strongest binder, while C4BP and
factor H showed similar yet lower relative intensities at clearly
distinct kinetics. Although kinetic rate constants could be extracted
for all three complement proteins (Supplementary Figure S1 and
Table S1), the absolute values have to be regarded with care due
to the rather high surface density of CS-A, its potential structural
heterogeneity, and the multivalency of its interaction with C1q
and C4BP. C1q showed a very fast association phase but also a
rather rapid dissociation phase. In contrast, complex formation
with C4BP appeared to be much slower. However, once formed,
the C4BP/CS-A complex was found to be highly stable. Finally,
factor H showed intermediate to rapid rates for both the
association and dissociation phase.
Binding of complement components to activated
platelets and blocking of the binding to CS-A with anti
CS-A mAbs
Platelets expose CS-A on their surfaces after activation by
thrombin, ADP, or other platelet activators. Exposure of CS-A
was monitored using two anti-CS-A mAbs recognizing different
epitopes of CS-A; mAbs CS-56 (Fig. 3A, B), and 2H6 (data not
shown). Binding of 2H6 to TRAP-activated platelets gave a mean
value of ,60 mean fluorescence intensity (MFI) units; the binding
of CS-56 was about five times higher. Binding of C1q (Fig. 3C, D)
to TRAP-activated platelets in platelet rich-plasma (PRP) was also
monitored in parallel to CS-A exposure on the platelets.
In order to investigate whether complement inhibitors bound to
the surface of activated platelets, non-activated, and TRAP-
activated platelets were subject to flow cytometry analyses.
Platelets in lepirudin anti-coagulated PRP were activated with
33.5 mM TRAP. In non-activated PRP, no binding of complement
inhibitors was observed when compared to the control using non-
specific antibody. In contrast, C1INH (p,0.05), C4BP (p,0.05),
and factor H (p,0.01)(Fig. 3E–J) bound to TRAP-activated
platelets. The binding of the complement inhibitors was also
confirmed using purified proteins and washed activated platelets
(data not shown); however, no binding of C1INH was detected
when washed, TRAP-activated platelets and purified protein were
used.
The binding of C1q, C4BP, and factor H was inhibited by
increasing concentrations of anti-CS-A mAb CS-56 (Fig. 4) but not
by mAb 2H6 (data not shown). The C4BP binding to the platelet
surface was significantly inhibited already with the lowest tested
antibody concentration (10 mg/mL; approximately 50% inhibi-
tion). To significantly inhibit also binding of C1q and factor H,
50 mg/mL was needed (50% and 70% inhibition, respectively).
Binding of HAGG to CS-A via C1q
In previous studies, it has been demonstrated that C1q can act
as an Fc receptor for IgG [18,19]. It is well established that upon
platelet activation, CS-A is rapidly exposed on the surface of the
cells. In order to test whether CS-A-bound C1q can act as an
immunoglobulin binding protein, CS-A immobilized in microtiter
plates was allowed to interact with heat-aggregated gamma
globulin (HAGG) in the presence and absence of C1q. We found
that the binding of HAGG was substantially amplified in the
presence of C1q (Fig. 5A, B). In similar experiments using
platelets, it was confirmed that C1q significantly increased the
binding of HAGG to the platelet surface, indicating that C1q can
act as a receptor for IgG (Fig. 5C). This binding was inhibited by
the anti-CS-A mAb CS-56 (Fig. 5D).
Discussion
CS-A is the major GAG exposed on activated platelets. The
present study was undertaken to determine whether CS-A
contributes to the binding of plasma proteins to activated platelets.
We have recently shown that C1q can be prevented from binding
to polystyrene surfaces conjugated with CS-A and to the surface of
activated platelets by soluble CS-A at very high concentrations
(50 mg/mL) [15]. In order to identify which plasma proteins are
potential candidates for binding to CS-A, we employed immobi-
lized CS-A to pull out proteins with an affinity/avidity for CS-A
from human serum.
CS-A conjugated to Sepharose was shown to bind a restricted
number of plasma proteins. When serum was passed over the CS-
A-conjugated and control Sepharose columns, immunoglobulin-
derived chains (m, a, c, and k) were found to bind to both columns.
In contrast, C1q was identified as the major specific CS-A-binding
protein by SDS-PAGE, followed by mass spectrometry analysis
and/or Western blotting. The affinity/avidity of C1q was superior
to those of the other proteins. The binding of C1q to CS-A was
independent of the presence of bound IgG, since depletion of IgG
from serum did not change the amounts of C1q that bound to CS-
Sepharose. This rules out that the immunoglobulins are natural,
polyreactive, antibodies against CS-A or Sepharose, which
potentially could bind C1q. Instead, it is likely that the bound
immunoglobulins are bound due to charge interactions which is
supported by the finding that there were more IgG than IgM,
resembling the normal proportions of the IgG and IgM
concentrations in serum/plasma, while most natural antibodies
belong to the IgM class [20].
Table 1. Proteins identified in CS-A and Sepharose eluate
after application of serum and C1q-depleted serum.
Protein Mass spectrometry Western blot
1. Fibronectin !!
2. Thrombospondin ! n.d.
3. Plasminogen ! n.d.
4. Thrombin-antithrombin complex !!
5. Ig m !!
6. Human serum albumin !!
7. Ig a !!
8. Ig c !!
9. C1q, chain A,B,C !!
10. Ig k ! n.d.
11. C1INH - !
12. C4BP - !
13. Factor H - !
Proteins 1–10 were visualized on a gel (Fig. 1A) by Commassie blue staining and
identified with mass spectrometric analysis. These proteins were also identified
with western blotting, except for thrombospondin, plasminogen and Ig k
chains that were not determined (n.d.). C1INH, C4BP and factor H were
identified with western blotting (Fig 1B).
doi:10.1371/journal.pone.0012889.t001
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high avidity for C1q binding to CS-A conjugated to the sensor
chip. Also, C4BP and factor H bound specifically to CS-A on the
sensor chip but at a lower response/molecular weight ratio than
that of C1q, further supporting C1q’s higher affinity for CS-A than
that of C4BP or factor H. In contrast to C1q and factor H, C4BP
demonstrated a slow dissociation from CS-A, revealing a rather
high stability of the complexes once they had formed.
The strong affinity of C1q for CS-A indicates a multivalent
binding to CS-A. C1q contains six collagenous stalks with globular
heads [21]. In a previous study we have demonstrated that C1q
binds to CS-A via the globular heads since we were able to block
this interaction by the monoclonal antibody Anti-C1q-85 which is
specific for the globular heads [15,22]. The affinity of a single
globular head for CS-A is not known, but that for IgG is in the
range of 10
23 M [23]. Assuming that the affinity for CS-A is
similar, the avidity (i.e., the combined affinities of the each of the
engaged globular heads in binding to CS-A) is very strong,
explaining the extremely high binding capacity of C1q for CS-A.
We also asked whether three complement proteins, all of which
are known to interact with different GAGs on activated platelets,
are exposed on the surface of TRAP-activated platelets in our
Figure 2. Surface plasmon resonance (SPR) analysis of complement proteins binding to immobilized CS-A. CS-A was immobilized to a
biosensor chip and analyzed for binding of monoclonal antibodies (CS-56 and 2H6) (A), purified C1q (B), C4BP (C), and factor H (D) using SPR.
Antibodies were tested from 33 nM; C1q and C4BP from 300 nM and factor H and C1INH from 900 nM, all in threefold dilutions. Binding response of
C1q, C4BP and factor H at a constant concentration (100 nM), were normalized by dividing the response by the molecular mass of the analyte (E).
Data are shown as mean, n=3.
doi:10.1371/journal.pone.0012889.g002
Complement Proteins and CS-A
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12889system. Exposure of C1q and factor H on activated platelets has
previously been documented [24,25,26], and factor H has also
been demonstrated on non-activated platelets. We have also
shown that C4BP is present on the activated platelet surface. In
order to link the binding of these proteins to exposure of CS-A, we
treated platelets with chondroitinase. This treatment led to loss of
CS-A, but the proteins and mAbs still bound to the surface of
activated platelets (data not shown). Obviously, there were still CS-
A remnants left, or else there is continuous recruitment of CS-A to
the surface of activated platelets. Instead, we used the CS-A-
specific mAbs CS-56 and 2H6 to block the binding of the three
candidate proteins. CS-56 and 2H6 bind to different distinct
epitopes of CS-A, which are present to various degrees depending
on the origin of CS-A [27]. CS-56, but not 2H6, showed specific
binding to immobilized CS-A as well as CS-A present on the
platelet surface. Preincubating CS-56 with platelets led to a
significant inhibition of the binding of C1q, C4BP, and factor H to
activated platelets.
Receptors and binding proteins for C1q, C4BP, and factor H on
platelets have previously been described. In the case of C1q,
several receptors have been identified that either recognize the
globular heads (e.g. gC1qR) or the collagenous portion (e.g.
cC1qR) [25,28,29]. C4BP has been shown to bind to membrane-
bound protein S [30], and factor H has been shown to interact
with GPIIb/IIIa [31]. The fact that mAb CS-56 was able to block
the binding of all three proteins to platelets indicates that CS-A
indeed represents a binding molecule on the surface of activated
platelets. Whereas C1q and factor H were only partially blocked
by mAb CS-56 and may likely have additional sites on platelets,
the observation that C4BP binding was almost completely
inhibited by this antibody suggests that CS-A is the primary
interaction site for C4BP on activated platelets.
C1q has previously been shown to be involved in the binding of
immune complexes to activated platelets [19,32]. In order to
confirm these reports, we allowed C1q to bind to CS-A in
microtiter plates, followed by exposure to HAGG. A pronounced
amplification of the binding of HAGG to the surfaces was
observed. This result clearly demonstrated the involvement of C1q
in the binding of HAGG to immobilized CS-A, bridging the
immune complex to the surface. Despite the obvious involvement
of several of the globular heads in binding to CS-A, sufficient
binding sites were present to bind HAGG in the microtiter plate
assay. In similar experiments, C1q and HAGG were allowed to
bind to activated platelets. A two-fold increase in the binding of
HAGG to activated platelets was obtained, confirming that C1q
acts as an immunoglobulin binding protein on platelets.
In order to connect the binding of HAGG to the CS-A-
mediated binding of C1q, we attempted to block the binding by
using a specific mAb against CS-A. A clear inhibition was
obtained, further linking the binding of C1q to CS-A with the
binding of HAGG. However, these experiments do not address
Figure 3. Exposure of CS-A and binding of complement
components on TRAP-activated platelets. Exposure of CS-A
(n=3)(A, B) and binding of complement components C1q (n=3)(C,
D), C1INH (n=5)(E, F), C4BP (n=5)(G, H), and factor H (n=8)(I, J) to non-
activated (black line) and TRAP-activated platelets (gray line) in
lepirudin-PRP, as detected by flow cytometry. Dotted lines indicate
the binding of species-matched negative control Abs to activated
platelets: sheep anti-mouse Ig (A, E, G, I) and rabbit anti-mouse Ig (C).
The difference in binding between the nonactivated and activated
samples was statistically significant (p,0.05). The flow cytometry
figures shown are representative of those obtained for each of the
bound components. *=p,0.05; **=p,0.01.
doi:10.1371/journal.pone.0012889.g003
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interaction with platelets.
Previous studies have demonstrated that the binding of immune
complexes to platelets has the capacity to activate platelets. Thus,
the binding of C1q to platelets is of potential pathological
importance for immune complex diseases such as SLE and
vasculitides. During exacerbations of these diseases, the levels of
immune complexes rise, resulting in binding of immune complexes
and activation of platelets [19,32]. This is indeed the case in SLE,
in which platelet activation is a common sign of disease
exacerbation.
Materials and Methods
Ethics statement
This study was approved by the Medical Ethical Committees at
the Universities of Linko ¨ping, and Uppsala, Sweden, and written
informed consent was given by the blood donors.
Blood samples
Blood was drawn from healthy volunteers who had received no
medication for at least 10 days prior to donation. It was collected
in 7-mL vacutainer tubes containing 100 mL of 5 mg/mL
lepirudin (Shering AG, Saksa, Germany). To obtain PRP, blood
was centrifuged at 1506g for 15 min at room temperature (RT)
within 30 min of collection.
Purified complement proteins
Human C1q was prepared from human serum as described by
Tenner et al. [33], and factor H was prepared from human serum
essentially according to Hammer et al. [34], except that the first
step consisted of a euglobulin precipitation as described by Nilsson
and Mu ˝ller-Eberhard [35]. Purified C4BP and C1INH were
purchased from Complement Technology, Inc. (Tyler, TX, USA).
Preparation of a CS-A affinity column
A CS-A affinity column (15-mL bed volume) was generated by
covalent coupling of CS-A via primary amines in the protein core to
CNBr-activated Sepharose
TM 4B (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The Sepharose was prepared according to the
manufacturer’s protocol. CS-A (450 mg), dissolved in 45 mL coupling
buffer (0.1 M sodium bicarbonate buffer, pH 8.3, containing 0.5 M
NaCl), was added to the prepared Sepharose (4500 mg) and allowed
to react with agitation for 2.5 hours. Any remaining reactive groups
on the Sepharose were blocked by overnight incubation at 4uCw i t h
0.1 M Tris-HCl, pH 8.0. Ionically bound CS-A was removed from
the Sepharose by repeated washing steps of alternating 0.1 M acetate
buffer, pH 4.5, containing 0.5 M NaCl and coupling buffer. A
column prepared using coupling buffer that was lacking CS-A was
used as a control. CS-A-affinity and control Sepharose preparations
were packed in glass econo columns (Bio-Rad, Hercules, CA, USA)
using gravity flow and equilibrated in 20 mM phosphate buffer
pH 7.4 containing 0.075 M NaCl and 10 mM EDTA.
Application of human serum or C1q-depleted serum to
the affinity column
Serum obtained from the Division of Clinical Immunology and
Transfusion Medicine, Uppsala University Hospital, was depleted of
C1q (99% depletion) as previously described [36]. Serum or C1q-
depleted serum was diluted 1:3 in 20 mM phosphate buffer pH 7.4
containing 0.075 M NaCl with 10 mM EDTA, and loaded in equal
amounts on CS-A and control column (45 mL of diluted serum per
column). Columns were washed with 75 mL of 20 mM phosphate
buffer pH 7.4 containing 0.075 M NaCl and 10 mM EDTA. The
bound proteinswereeluted in1-mLfractionswith20 mMphosphate
buffer pH 7.4 containing 1.0 M NaCl and 10 mM EDTA. The
amount of eluted protein in each fraction was estimated by
absorbance measurements at 280 nm. In both cases, eight fractions
with the highest protein content were pooled and concentrated to
500 mL using Amicon Ultra Centrifugal Filters (10-kDa cut-off)
(Millipore AB, Sundbyberg, Sweden). IgG dependent binding of C1q
to CS-A was investigated by loading intact serum and serum which
Figure 4. Inhibition of the binding of complement components
to platelets by an anti-CS-A mAb. Platelets were preincubated with
anti-CS-A mAb CS-56 in the indicated concentrations. After washing,
C1q (n=5)(A), C4BP (n=6)(B), or factor H (n=4)(C) was added, and the
bound protein was detected using the appropriate antibody. Data
shown as means 6 SEM, *=p,0.05; **=p,0.01.
doi:10.1371/journal.pone.0012889.g004
Complement Proteins and CS-A
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12889had been depleted of IgG using a HiTrap protein G sepharose
column (GE Healthcare) on CS-A Sepharose. The amount of C1q in
the eluate was measured by ELISA as previously described [37].
SDS-PAGE and Western blotting
Concentrated proteins from the CS-A and control column were
separated by SDS-PAGE under reducing conditions. Proteins
were either detected with Coomassie brilliant blue or transferred
to PVDF membranes (Bio-Rad), then blocked with 1% bovine
serum albumin (BSA). The membranes were incubated with rabbit
anti-C1q (Dako, A/S Glostrup, Denmark), goat anti-C1INH
(Enzyme Research Laboratories, South Bend, IL, USA), rabbit
anti-C4BP (The Binding Site, Birmingham, UK), or sheep anti-
factor H (The Binding Site), all of which were biotinylated.
Membranes were thereafter incubated with HRP-conjugated
streptavidin (GE Healthcare) and developed with diaminobenzi-
dine (Sigma-Aldrich Inc, St. Louis, MO, USA).
In-gel digestions
Proteins that had been separated by SDS-PAGE and visualized
with Commassie brilliant blue staining were subjected to in-gel
digestion and identified by either MALDI-MS/MS or LC-ESI-
MS/MS. In-gel digestion was performed according to UCSF in-
gel digestion protocol (http://donatello.ucsf.edu/ingel.html; ac-
cessed April 27, 2010). In brief, excised bands were dehydrated
with 25 mM NH4HCO3 in 50% acetonitrile, reduced with
10 mM DTT at 56uC for 60 minutes and alkylated with 55 mM
iodoacetamide at RT for 45 minutes in the dark. Proteolytic
cleavage was carried out by over night incubation with trypsin
(sequencing grade modified trypsin (16 ng/mL), Promega, Madi-
son, WI, USA) at 37uC. Peptides were then extracted by the
addition of 50% acetonitrile containing 5% formic acid. The
solvent was evaporated to dryness in a vacuum concentrator and
the extracted peptides were redissolved in 0.1% trifluoroacetic acid
(TFA). When necessary, the samples were desalted using
ZipTipC18 (Millipore, Bedford, MA, USA).
Mass spectrometry and protein identification
Mass spectrometric analysis of in-gel digests was performed using
a SYNAPT HDMS (Waters Corp., Milford, MA, USA) controlled
by MassLynx software v 4.1 (Waters) and equipped either with a
MALDI or nanoESI source. A nanoACQUITY UPLC (Waters)
system was used for peptide separation by reversed-phase liquid
chromatography. After injection, peptides were trapped for 3 min
with 3% mobile phase A at 5 mL/min on a 5 mm Symmetry C18
column (180 mm620 mm, Waters) and further separated on a
1.7 mm BEH130 C18 column (75 mm6150 mm, Waters). The
analytical column temperature was held at 35uC. Mobile phase A
was 0.1% formic acid in water and B was 0.1% formic acid in
acetonitrile. Peptides were separated with a 40 min gradient (3–
40%) at flow rate 0.3 mL/min and eluted into the nanoESI source.
The capillary voltage was 3.2 kV, the cone voltage was 37 V and
the source temperature was set to 100uC. [Glu
1]-fibrinogen peptide
was used for lock-mass correction witha sampling rate of 30 s. Mass
spectra were acquired in positive mode and data dependant analysis
was used for selection of precursors. MS survey data was acquired
Figure 5. HAGG binding to immobilized CS-A and to the surface of activated platelets. C1q-dependent binding of HAGGs to CS-A. HAGGs
were incubated with varying concentrations of C1q in microtiter plates bearing immobilized CS-A (A–B). HAGG in constant concentration, with C1q in
dilution series (A) and C1q in constant concentration, with that of HAGG in dilution series (B). Binding of HAGGs to CS-A increased with increasing
concentration of C1q. Binding of HAGGs at the indicated concentrations to washed activated platelets with and without the addition of C1q (C). The
binding of HAGGs was inhibited by incubating washed TRAP-activated platelets with increasing concentrations of anti-CS-A mAb CS-56 prior to the
addition of C1q and HAGG (D). Data shown are means 6 SEM, (n=3 (A–B), n=5 (C–D); *=p,0.05; **=p,0.01; ***=p,0.001).
doi:10.1371/journal.pone.0012889.g005
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charge +2, +3o r+4 was obtained by collision energy ramp from 15
to 40 V over a m/z range of 50–2000. The dynamic exclusion
window was set to 60 s. For MALDI-MS/MS analysis 1 mLo f
sample was mixed with 1 mL of matrix solution (saturated CHCA in
50% ACN, 0.1% TFA) on the target plate. Mass spectra were
acquired in positive mode over the mass range m/z 700–3500 at
scan rate 2 s. Three precursors showing peak intensity threshold
above 15 counts were selected for fragmentation and the MS/MS
spectrum was acquired between m/z 50 and the precursor mass.
Data processing and analysis was carried out by PLGS (Waters)
software version 2.3. Processed data was searched with Mascot
(matrix science) search engine against Swiss-Prot database with the
following parameters: human taxonomy; 20 ppm precursor mass
tolerance; 0.25 Da fragment ion tolerance; trypsin enzyme; one
missed cleavage allowed; carbamidomethylation of cysteine and
oxidation of methionine as variable modifications. Protein identi-
fication criteria were based on Mascot score above the threshold
(p,0.05) and a minimum of one peptide fragmentation spectrum.
Interaction analysis of CS-A with complement proteins
using surface plasmon resonance
Surface plasmon resonance (SPR) analysis was performed on a
Biacore X biosensor (Biacore AB, Uppsala, Sweden) with CS-A
immobilized onto a carboxylated hydrogel sensorchip (HC500;
XanTec bioanalytics GmbH, Munster, Germany). The sensor chip
was conditioned and activated for 10 minutes using sulfo-NHS
amine coupling kit (XanTec) according to the manufacturers’
protocol. A 50 mL injection of CS-A (100 mg/mL) dissolved in
20 mM phosphate buffer pH 7.0 was performed in one flow cell
followed by quenching with 1 M ethanolamine hydrochloride
pH 8.5, whereas the other flow cell served as control and was
quenched by ethanolamine after activation. Approximately 600 RU
of CS-A was immobilized, and the successful immobilization was
verified by an anti-CS-A mAb (CS-56; Sigma-Aldrich). All
interaction studies were performed in HBS buffer (10 mM HEPES
pH 7.4, 150 mM NaCl, 0.005% Tween-20) at 20uC and a flow rate
of 20 mL/min. Purified proteins C1q (1.2–300 nM), C4BP (1.2–
300 nM), C1INH (3.7–900 nM), factor H (3.7–900 nM) as well as
antibodies CS-56 (1.2–33 nM) and 2H6 (Seikagaku Corp. Tokyo,
Japan; 1.2–33 nM), which recognize different epitopes of CS-A
[27], were analyzed as threefold dilution series. Each analyte
concentration was injected in triplicates for 60 s with a dissociation
time of 180 s. The sensor surface was regenerated using repetitive
injections of 1 M NaCl in 50 mM sodium acetate buffer pH 4.5
and/or 1 M NaCl in 0.1 M sodium borate pH 9.0. All sensorgrams
were processed using the double referencing method [38] where
background contribution and buffer artifacts are eliminated by
subtracting signals from the reference flow cell and from buffer
blank injections. Kinetic parameters were analyzed using ClampXP
(version 3.5) [39]. The data for all binding proteins were fitted with
the surface heterogeneity model, describing immobilized ligand (B)
existing in different forms with different rate constants for
interacting with the analyte, represented as equation 1 [40].
AzB1 '
ka1
kd1
AB1 and AzB2 '
ka2
kd2
AB2 ð1Þ
Platelet activation and preparation
Platelets were activated in whole blood or PRP anticoagulated
with lepirudin at 37uC by adding thrombin receptor activating
peptide-6 (TRAP; (SFLLRN), Invitrogen, Molecular Probes,
Carlsbad, CA, USA) to a final concentration of 25 mg/mL
(33.5 mM). Activation was stopped by the addition of EDTA
(10 mM). The PRP was centrifuged at 11006g for 10 min at RT,
and the plasma was removed.
After activation and centrifugation, the platelet-containing
pellets were washed three times with Tyrode’s medium I
(pH 6.5), containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2,
0.36 mM NaH2PO4, 12 mM NaHCO3, 2 mM CaCl2, 5.5 mM
glucose, 3.5 mg/ml BSA (Sigma-Aldrich), 1 mM PGE1 (Sigma-
Aldrich), and 2 IU/mL heparin (Bioiberica, Barcelona, Spain).
Each wash cycle consisted of suspension of the pellet in the
Tyrode’s medium and incubation at 37uC for 10 min, followed by
centrifugation at 11006g at RT for 10 min. In some experiments,
the platelets were washed prior to activation. Platelets were
pelleted from PRP by centrifugation at 11006g for 10 min and
washed three times as described above to remove plasma proteins.
After washing, the platelets were pelleted and resuspended in
Tyrode’s medium I without the addition of BSA, heparin, or
PGE1. The platelets were then activated by the addition of TRAP
and incubated as described above. After activation, they were
washed once and resuspended in Tyrode’s medium I with BSA,
heparin, and PGE1. Activated and non-activated platelets were
diluted to 200610
9/L, and purified C1q (10 mg/mL), C1INH
(20 mg/mL), C4BP (20 mg/mL), or factor H (20 mg/mL) was
added to the platelets and incubated for 30 min at RT. In a few
experiments, platelets were pre-incubated with anti-CS-A mAb
CS-56 (Sigma-Aldrich), (10, 25, 50 or 100 mg/mL) on a shaker for
30 min at RT prior to the addition of C1q, C4BP, or factor H to
the platelets. Platelets were then washed and labeled with
antibodies as described below. In order to determine whether
C1q bound to activated platelets could act as an Fc receptor for
IgG, we added model complexes in the form of heat-aggregated
gamma globulin (HAGGs; 0–10 mg/mL) to activated platelets that
been incubated with or without C1q (10 mg/mL) followed by
washing, then incubated the platelets and complexes for 30 min at
RT. After washing, the binding of HAGG was detected with
rabbit anti-human IgG (Fab2)-FITC (Dako). In a few experiments
platelets were incubated with anti-CS-A mAb CS-56 (25, 50 and
100 mg/mL) prior to the addition of C1q (10 mg/mL) and
subsequently HAGG (10 mg/mL).
FACS analysis of platelet-bound complement proteins
Flow cytometry was used to monitor the activation of platelets
and detect the binding of complement proteins to non-activated
platelets or platelets activated with 33.5 mM TRAP. Platelets
(100 mL, 50610
9 platelets/L) were incubated for 60 min at RT
with the following antibodies: mouse anti-human P-selectin-RPE
(Dako) or AlexaFluor 488-labeled rabbit anti-human C1q (Dako).
Binding of the complement regulators was detected with
biotinylated sheep polyclonal antibodies against human factor H,
human C1INH, and human C4BP (The Binding Site). Exposure
of chondroitin sulfate on TRAP-activated platelets was monitored
with biotinylated IgM monoclonal anti-CS-A antibody 2H6
(Seikagaku Corp) or with IgM monoclonal anti-CS-A antibody
CS-56 followed by sheep anti-mouse Ig-FITC. Streptavidin-FITC
(GE Healthcare) was used to detect the bound biotinylated
antibodies. FITC-labeled sheep anti-mouse Ig (The Binding Site),
rabbit anti-mouse Ig (Dako), and mouse IgG1 (Dako), and
biotinylated mouse IgG1 and goat anti-rabbit Ig were used as
negative controls, each at a final concentration of 10 mg/mL. In
each experiment, the activation status of the platelets (control and
experimental) was ascertained by monitoring the expression of P-
selectin. After staining, the platelets were washed and fixed with
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bound fluorochrome-labeled antibodies were monitored with a
FACSCalibur (Becton Dickinson, San Jose, CA, USA) and BD
CellQuest Pro software. In each sample, ,30,000 cells were
analyzed.
Biotinylation of CS-A and preparation of CS-A-coated
microtiter plates
CS-A sodium salt (Sigma-Aldrich) was biotinylated via the
primary amines in the protein core as follows: CS-A (20 mg) was
dissolved in 0.1 M phosphate buffer pH 7.6 (2 mL), and 1.7 mg
biotinamidohexanoic acid N-hydroxysuccinimide ester (Sigma-
Aldrich) was added to the solution. The reaction was allowed to
take place over 10 hr at 4uC. Unconjugated biotin and reaction
byproducts were removed with a PD-10 desalting column (GE
Healthcare).
Microtiter plates (Nunc Maxisorb Immunoplate, Nunc, Copen-
hagen, Denmark) were coated with 100 mL streptavidin (Sigma-
Aldrich; 5 mg/mL). Wells were then blocked with 10 mM
phosphate buffer containing 1% BSA, 0.05% Tween 20 (Sigma-
Aldrich), and 0.145 M NaCl, for 30 min at RT. Biotinylated CS-A
(100 mL, 5 mg/mL) was subsequently bound to the streptavidin
layer by incubation for 60 min at RT.
C1q-dependent binding of HAGG to immobilized CS-A
Purified C1q and HAGG were diluted in PBS. C1q was
incubated in CS-A-coated wells at a constant concentration (0.05,
0.5, or 5 mg/mL) or in a two-fold dilution series (0.31–20 mg/mL)
for 15 min at RT. HAGG at a constant concentration (0.05, 0.5,
or 5 mg/mL) or in a two-fold dilution series (0.31–20 mg/mL) was
added to the wells with the C1q in dilution series or a constant
concentration, respectively, and incubated for 60 min at RT. After
washing, bound HAGG was detected using rabbit anti-human IgG
(Dako) followed by HRP-conjugated swine anti-rabbit antibody
(Dako). Washing and dilution of the antibodies were done using
PBS with 0.05% Tween-20. Phenylenediamine dihydrochloride in
0.1 M citrate, pH 5, was used as the color substrate.
Statistical analysis
Results are presented as means 6 SEM. Differences between
means were statistically evaluated using the paired Student’s t-test
or repeated measures ANOVA, followed by Bonnferroni’s
multiple comparison test for calculating differences in data
containing more than two variables. For statistical analysis, Prism
4 for Macintosh software (Graphpad, San Diego, CA, USA) was
used. In the experiments in which platelets were used, the n-values
refer to independent experiments using platelets from different
blood donors.
Supporting Information
Table S1 Binding parameters of C1q, C4BP and factor H to
immobilized CS-A.
Found at: doi:10.1371/journal.pone.0012889.s001 (0.03 MB
DOC)
Figure S1 Sensorgrams fitted to the surface heterogeneity model
using ClampXP software. CS-A immobilized to a biosensor chip
and analysed for binding of purified C1q (1.2–300 nM; A), C4BP
(1.2–300 nM; B), and factor H (3.7–900 nM; C) using SPR. Data
are shown as mean, n=3. C1q sensorgrams representing 100 and
300 nM were, based on the high response, excluded in the final
fitting. Experimental data are shown as dashed black lines and fit
as solid grey lines. Sensorgrams were fitted using heterogeneity
model, describing different form of immobilized ligand able to
interact with the analyte with separate rate constants. This
assumption is due to the structural diversity that exists among
CS-A.
Found at: doi:10.1371/journal.pone.0012889.s002 (0.24 MB TIF)
Acknowledgments
We are grateful to Dr. Deborah McClellan for editorial assistance.
Author Contributions
Conceived and designed the experiments: OAH PHN BN KNE.
Performed the experiments: OAH PHN ML. Analyzed the data: OAH
PHN ML DR JL BN KNE. Contributed reagents/materials/analysis tools:
ML DR JL. Wrote the paper: OAH PHN BN KNE.
References
1. Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their
interactions with proteins. Chem Biol Drug Des 72: 455–482.
2. Lamari FN, Karamanos NK (2006) Structure of chondroitin sulfate. Adv
Pharmacol 53: 33–48.
3. Sugahara K, Mikami T, Uyama T, Mizuguchi S, Nomura K, et al. (2003)
Recent advances in the structural biology of chondroitin sulfate and dermatan
sulfate. Curr Opin Struct Biol 13: 612–620.
4. Taylor KR, Gallo RL (2006) Glycosaminoglycans and their proteoglycans: host-
associated molecular patterns for initiation and modulation of inflammation.
Faseb J 20: 9–22.
5. Lamari FN, Theocharis AD, Asimakopoulou AP, Malavaki CJ, Karamanos NK
(2006) Metabolism and biochemical/physiological roles of chondroitin sulfates:
analysis of endogenous and supplemental chondroitin sulfates in blood
circulation. Biomed Chromatogr 20: 539–550.
6. Malmstrom A, Aberg L (1982) Biosynthesis of dermatan sulphate. Assay and
properties of the uronosyl C-5 epimerase. Biochem J 201: 489–493.
7. Sherman LS, Back SA (2008) A ‘GAG’ reflex prevents repair of the damaged
CNS. Trends Neurosci 31: 44–52.
8. Okayama M, Oguri K, Fujiwara Y, Nakanishi H, Yonekura H, et al. (1986)
Purification and characterization of human platelet proteoglycan. Biochem J
233: 73–81.
9. Ward JV, Packham MA (1979) Characterization of the sulfated glycosamino-
glycan on the surface and in the storage granules of rabbit platelets. Biochim
Biophys Acta 583: 196–207.
10. Donato JL, Nogueira MD, Marcondes S, Antunes E, Nader HB, et al. (1994)
The kinetics of chondroitin 4-sulfate release from stimulated platelets and its
relation to thromboxane A2 formation and granule secretion. Braz J Med Biol
Res 27: 2163–2167.
11. MacPherson GG (1972) Synthesis and localization of sulphated mucopolysac-
charide in megakaryocytes and platelets of the rat, an anlysis by electron-
microscope autoradiography. J Cell Sci 10: 705–717.
12. Woulfe DS, Lilliendahl JK, August S, Rauova L, Kowalska MA, et al. (2008)
Serglycin proteoglycan deletion induces defects in platelet aggregation and
thrombus formation in mice. Blood 111: 3458–3467.
13. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, et al.
(2008) Contaminated heparin associated with adverse clinical events and
activation of the contact system. N Engl J Med 358: 2457–2467.
14. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, et al. (2008)
Complement activation triggered by chondroitin sulfate released by thrombin
receptor-activated platelets. J Thromb Haemost 6: 1413–1421.
15. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, et al.
Complement component C3 binds to activated normal platelets without
preceding proteolytic activation and promotes binding to complement receptor
1. J Immunol 184: 2686–2692.
16. Anderluh M, Dolenc MS (2002) Thrombin receptor antagonists; recent
advances in PAR-1 antagonist development. Curr Med Chem 9: 1229–
1250.
17. Suzuki H, Packham MA, Kinlough-Rathbone RL (1995) Effects of thrombin
and the thrombin receptor activating peptide, SFLLRN, on redistribution of
platelet alpha-granule contents are similar and independent of the extent of
thromboxane formation. Exp Mol Pathol 62: 63–72.
18. Peerschke EI, Ghebrehiwet B (1992) Platelet interactions with C1q in whole
blood and in the presence of immune complexes or aggregated IgG. Clin
Immunol Immunopathol 63: 45–50.
19. Peerschke EI, Ghebrehiwet B (1997) C1q augments platelet activation in
response to aggregated Ig. J Immunol 159: 5594–5598.
Complement Proteins and CS-A
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e1288920. Notkins AL (2004) Polyreactivity of antibody molecules. Trends Immunol 25:
174–179.
21. Tissot B, Gonnet F, Iborra A, Berthou C, Thielens N, et al. (2005) Mass
spectrometry analysis of the oligomeric C1q protein reveals the B chain as the
target of trypsin cleavage and interaction with fucoidan. Biochemistry 44:
2602–2609.
22. McGrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, et al. (2006)
Evidence that complement protein C1q interacts with C-reactive protein
through its globular head region. J Immunol 176: 2950–2957.
23. Kishore U, Leigh LE, Eggleton P, Strong P, Perdikoulis MV, et al. (1998)
Functional characterization of a recombinant form of the C-terminal, globular
head region of the B-chain of human serum complement protein, C1q.
Biochem J 333(Pt 1): 27–32.
24. Devine DV, Rosse WF (1987) Regulation of the activity of platelet-bound C3
convertase of the alternative pathway of complement by platelet factor H. Proc
Natl Acad Sci U S A 84: 5873–5877.
25. Peerschke EI, Ghebrehiwet B (1994) Platelet membrane receptors for the
complement component C1q. Semin Hematol 31: 320–328.
26. Vaziri-Sani F, Hellwage J, Zipfel PF, Sjoholm AG, Iancu R, et al. (2005) Factor
H binds to washed human platelets. J Thromb Haemost 3: 154–162.
27. Deepa SS, Yamada S, Fukui S, Sugahara K (2007) Structural determination of
novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage
and their application for characterizing monoclonal antibody epitopes.
Glycobiology 17: 631–645.
28. Peerschke EI, Ghebrehiwet B (1987) Human blood platelets possess specific
binding sites for C1q. J Immunol 138: 1537–1541.
29. Peerschke EI, Ghebrehiwet B (1988) Identification and partial characterization
of human platelet C1q binding sites. J Immunol 141: 3505–3511.
30. Dahlback B, Frohm B, Nelsestuen G (1990) High affinity interaction between
C4b-binding protein and vitamin K-dependent protein S in the presence of
calcium. Suggestion of a third component in blood regulating the interaction.
J Biol Chem 265: 16082–16087.
31. Mnjoyan Z, Li J, Afshar-Kharghan V (2008) Factor H binds to platelet integrin
alphaIIbbeta3. Platelets 19: 512–519.
32. Lindahl TL, Larsson A (1993) C1q Binding to Platelets Induced by Monoclonal-
Antibodies and Immune-Complexes - a Flow Cytometric Analysis. Platelets 4:
73–77.
33. Tenner AJ, Lesavre PH, Cooper NR (1981) Purification and radiolabeling of
human C1q. J Immunol 127: 648–653.
34. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF (1981) Large scale
isolation of functionally active components of the human complement system.
J Biol Chem 256: 3995–4006.
35. Nilsson UR, Mueller-Eberhard HJ (1965) Isolation of Beta If-Globulin from
Human Serum and Its Characterization as the Fifth Component of
Complement. J Exp Med 122: 277–298.
36. Sjoholm AG, Selander B, Ostenson S, Holmstrom E, Soderstrom C (1991)
Normal human serum depleted of C1q, factor D and properdin: its use in studies
of complement activation. Apmis 99: 1120–1128.
37. Henningsson AJ, Ernerudh J, Sandholm K, Carlsson SA, Granlund H, et al.
(2007) Complement activation in Lyme neuroborreliosis–increased levels of C1q
and C3a in cerebrospinal fluid indicate complement activation in the CNS.
J Neuroimmunol 183: 200–207.
38. Myszka DG (1999) Improving biosensor analysis. J Mol Recognit 12: 279–284.
39. Myszka DG, Morton TA (1998) CLAMP: a biosensor kinetic data analysis
program. Trends Biochem Sci 23: 149–150.
40. Morton TA, Myszka DG, Chaiken IM (1995) Interpreting complex binding
kinetics from optical biosensors: a comparison of analysis by linearization, the
integrated rate equation, and numerical integration. Anal Biochem 227:
176–185.
Complement Proteins and CS-A
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12889